ALTERITY THERAPEUTICS LTD (ATHE)
Alterity Therapeutics Limited, an Australian biopharmaceutical firm, focuses on the discovery and development of novel drug treatments for various neurological disorders, such as Alzheimer's, Huntington's, and Parkinson's diseases. Its prominent experimental therapy, ATH434, has completed Phase I clinical trials targeting Parkinson's disease. The company is also advancing PBT2, a compound that has successfully undergone Phase IIa clinical testing for Alzheimer's disease. Established in 1997, the entity was formerly known as Prana Biotechnology Limited before rebranding to Alterity Therapeutics Limited in April 2019, and its main operations are based in Melbourne, Australia.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Alterity Therapeutics Limited
1-25 of 1,173 filings
Recent SEC filings with analysis
- 6-KAlterity Therapeutics announced that CEO David Stamler will present at the virtual Bell Potter Healthcare Conference on November 19, 2026, with an archived…
- 6-KAlterity Therapeutics reported that FDA End-of-Phase 2 meeting minutes confirmed agreement on the Phase 3 trial design and registrational pathway for ATH434 in…
- 6-KAlterity Therapeutics Limited, an Australia-based development-stage biotech, filed a Form 6-K on October 23, 2026 reporting a proposed issue of securities…
- 6-KAlterity Therapeutics filed a Form 6-K for October 2026 as a foreign private issuer, incorporating the filing into its existing S-8 and F-3 registration…
- 6-KAlterity Therapeutics Limited filed a Form 6-K for October 2026 as a foreign private issuer.
- 6-KAlterity Therapeutics filed a Form 6-K for October 2026 furnishing its Notice of Annual General Meeting and accompanying proxy form as Exhibit 99.1.
- 6-KAlterity Therapeutics announced changes to CEO and Managing Director Dr David Stamler's remuneration package, effective 15 October 2026, following a board…
- 6-KAlterity Therapeutics announced that CEO David Stamler will participate in a fireside chat at the Craig-Hallum Virtual Biotech Catalyst Conference on Thursday,…